Intel is refusing to walk away from Elon Musk's "Terafab" concept, keeping its hand in a hyperscale chipmaking venture even as TSMC emerges as a rival suitor for the business — and investors have responded by pushing INTC stock higher, TipRanks reports.

The dispute centers on Musk's ambition to build a "terafab" — a fabrication plant of unprecedented scale that his AI venture, xAI, would need to feed its GPU-hungry training clusters. Intel has positioned itself as a natural partner: it controls idle U.S. capacity and has spent years courting external foundry customers through Intel Foundry Direct.

What has changed?

TSMC has now entered the frame, according to the report. The world's largest contract chipmaker — which already manufactures the overwhelming majority of Nvidia's advanced AI accelerators — represents a formidable alternative for Musk, given its process leadership at leading-edge nodes and its proven ability to ramp high-volume AI silicon.

Intel's response has been to stand firm rather than fold. Rather than treating TSMC's interest as a knockout blow, Intel continues to advance its own pitch for the terafab project. The company has not publicly detailed the financial terms under discussion, and no deal has been announced.

Why does Musk's business matter to Intel?

For Intel, the stakes extend beyond a single customer contract:

• A Musk-backed terafab would anchor Intel Foundry with a marquee, multi-year commitment at a moment when its foundry arm is still scaling.
• Winning AI-infrastructure volume would strengthen Intel's case to investors that its capital-intensive fab buildout can generate external revenue.
• Losing the project to TSMC would hand a flagship AI workload to the competitor that already dominates advanced AI manufacturing.

The market read the standoff constructively: INTC shares gained on the news, suggesting investors see Intel's persistence — and the mere fact that Musk's megafab is in play — as a net positive for the stock.

How real is the terafab?

The project remains a concept rather than a committed capital plan. Musk has not confirmed a site, a process node, a wafer size, or an investment figure for the terafab, and neither Intel nor TSMC has confirmed the parameters of any negotiation. What is confirmed, per the TipRanks report, is the competitive dynamic: Intel standing firm, TSMC entering the frame, and Intel's stock moving higher as a result.

For Intel, the immediate commercial question is whether standing its ground converts into a signed foundry agreement before TSMC's manufacturing track record in AI silicon wins the account.